Form 4: Amylyx Pharmaceuticals Director George Milne Jr. Granted 25,000 Stock Options
Insider Transaction Report
Amylyx Pharmaceuticals, Inc. Director George M. Milne Jr. was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026.
Summary
- George M. Milne Jr., a Director of Amylyx Pharmaceuticals, Inc. (AMLX), was granted 25,000 stock options on June 5, 2025.
- The stock options have an exercise price of $5.05 per share.
- These options are set to vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, contingent on Mr. Milne's continuous service to the Issuer.
- The options have an expiration date of June 4, 2035.
- Following this transaction, Mr. Milne beneficially owns 25,000 derivative securities (stock options) directly.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value creation, indicating standard corporate governance practices.
Positives
- The grant of 25,000 stock options to Director George M. Milne Jr. aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company's success.
Future Outlook
NA
Industry Context
This Form 4 filing is a standard disclosure of an insider transaction, specifically the grant of stock options to a director, which is a common form of executive and director compensation in the biotechnology and pharmaceutical industry to align interests with long-term company performance.
Related Party Transactions
- The grant of 25,000 stock options to George M. Milne Jr., a Director of Amylyx Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to an insider.
Stakeholder Impact
- Shareholders: The grant of stock options aims to align the director's long-term interests with shareholder value creation.
- Employees: No direct impact on general employees is mentioned in this filing.
Next Steps
- The stock options granted to George M. Milne Jr. are scheduled to vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, subject to his continuous service.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date of earliest transaction (grant of stock options) |
| 06/09/2025 | Date the Form 4 was signed by the attorney-in-fact |
| 06/05/2026 | Earliest potential full vesting date for the stock options |
| 06/04/2035 | Expiration date of the granted stock options |
Keywords
Amylyx Pharmaceuticals, AMLX, Form 4, stock options, insider transaction, director compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.